Chuansheng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chuansheng Wang has a total of 176 co-authors. Here are the top co-authors by number of shared publications:
- Fang Yan
Xinxiang Mental Rehabilitation Key Laboratory, the Second Affiliated Hospital of Henan Medical University, Xinxiang, China
5 shared publications Yue Zhou
The Second Affiliated Hospital of Henan Medical University
5 shared publicationsHanshuo Su
Department of Early Intervention, Mental Health and Artificial Intelligence Research Center, The Second Affiliated Hospital of Xinxiang Medical University, Henan Mental Hospital
3 shared publicationsHongdu Deng
The Second Affiliated Hospital of Henan Medical University Xinxiang Henan China
3 shared publicationsJiali Wang
The Second Affiliated Hospital of Henan Medical University Xinxiang Henan China
3 shared publicationsJuan Wang
The Second Affiliated Hospital of Henan Medical University
3 shared publications
Latest Publications
- Open Access
- 9 June 2026
- Published by Elsevier in Sleep Medicine
- Vol. 146, 109077
Efficacy and safety of atomoxetine combination therapy for obstructive sleep apnea: A meta-analysis of randomized placebo-controlled trials
- 9 June 2026
- Published by Elsevier in Sleep Medicine
- Vol. 146, 109077
Open AccessEfficacy and safety of atomoxetine combination therapy for obstructive sleep apnea: A meta-analysis of randomized placebo-controlled trials
- Open Access
- 5 June 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1828667
A study on the effects of combined DBT and STEPPS interventions for adolescents with non-suicidal self-injury: a randomized controlled trial
Objective: To evaluate whether an integrated Dialectical Behavior Therapy and Systems Training for Emotional Predictability and Problem Solving (DBT + STEPPS) programme is more effective than DBT alone or conventional treatment in reducing non-suicidal self-injury (NSSI) and improving emotion regulation, anxiety, and depressive symptoms among adolescents with depression and NSSI. Methods: This study recruited 192 adolescent patients with non-suicidal self-injury between March 2024 and February 2025, and they were randomly divided into the Control Group (conventional intervention), Intervention Group A (DBT intervention), and Intervention Group B (DBT combined with STEPPS intervention). Patients’ self-harm behaviors, emotional regulation strategy capabilities, and severity of illness were assessed both prior to intervention and within 48 h post-intervention. Data analysis employed one-way analysis of variance (ANOVA), Kruskal–Wallis H test, χ 2 test, or Fisher’s exact test. Results: Intervention Group B exhibited lower NSSI behavior scores than both Intervention Group A and the control group, while Intervention Group A scored lower than the control group ( p < 0.05). Regarding emotional regulation capacity, Intervention Group B demonstrated the highest adaptive strategy scores and the lowest maladaptive strategy scores ( p < 0.05). This group also recorded the lowest anxiety and depression symptom scores ( p < 0.05). All indicators for Intervention Group A were superior to those of the control group ( p < 0.05). Conclusion: DBT combined with STEPPS effectively reduces NSSI behaviors, improves emotion regulation, and alleviates anxiety and depression in adolescent non-suicidal self-injurious patients. And the effect of the combined intervention is better than that of the single intervention. Clinical trial registration: This study was registered with the Chinese Clinical Trial Registry ( https://www.chictr.org.cn/ ; Registration number: ChiCTR2100043855) on 4 March 2021. The first subject was recruited on February 13, 2025.
- 5 June 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1828667
Open AccessA study on the effects of combined DBT and STEPPS interventions for adolescents with non-suicidal self-injury: a randomized controlled trial
Objective: To evaluate whether an integrated Dialectical Behavior Therapy and Systems Training for Emotional Predictability and Problem Solving (DBT + STEPPS) programme is more effective than DBT alone or conventional treatment in reducing non-suicidal self-injury (NSSI) and improving emotion regulation, anxiety, and depressive symptoms among adolescents with depression and NSSI. Methods: This study recruited 192 adolescent patients with non-suicidal self-injury between March 2024 and February 2025, and they were randomly divided into the Control Group (conventional intervention), Intervention Group A (DBT intervention), and Intervention Group B (DBT combined with STEPPS intervention). Patients’ self-harm behaviors, emotional regulation strategy capabilities, and severity of illness were assessed both prior to intervention and within 48 h post-intervention. Data analysis employed one-way analysis of variance (ANOVA), Kruskal–Wallis H test, χ 2 test, or Fisher’s exact test. Results: Intervention Group B exhibited lower NSSI behavior scores than both Intervention Group A and the control group, while Intervention Group A scored lower than the control group ( p < 0.05). Regarding emotional regulation capacity, Intervention Group B demonstrated the highest adaptive strategy scores and the lowest maladaptive strategy scores ( p < 0.05). This group also recorded the lowest anxiety and depression symptom scores ( p < 0.05). All indicators for Intervention Group A were superior to those of the control group ( p < 0.05). Conclusion: DBT combined with STEPPS effectively reduces NSSI behaviors, improves emotion regulation, and alleviates anxiety and depression in adolescent non-suicidal self-injurious patients. And the effect of the combined intervention is better than that of the single intervention. Clinical trial registration: This study was registered with the Chinese Clinical Trial Registry ( https://www.chictr.org.cn/ ; Registration number: ChiCTR2100043855) on 4 March 2021. The first subject was recruited on February 13, 2025.
- Open Access
- 26 May 2026
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 17, 1778443
Task-state P300 and functional brain network abnormalities in adolescent major depressive disorder: a Stroop paradigm study
Background: Cognitive control deficits are a core feature of adolescent major depressive disorder (MDD), yet the associated task-state neurophysiological mechanisms remain poorly characterized. This study investigated electrophysiological alterations in MDD using a Stroop color-word task. Methods: Twenty-two adolescents with MDD and fifteen age- and sex-matched healthy controls (HC) completed the task during 32-channel EEG recording. We analyzed P300 amplitude and latency, 1-30Hz power spectral density (PSD) in key cortical regions, and task-based functional connectivity using the phase locking value (PLV). A support vector machine (SVM) classifier with leave-one-out cross-validation was employed to assess the diagnostic utility of the multimodal features. Results: Relative to HC, the MDD group exhibited significantly prolonged incongruent trial reaction times, reduced P300 amplitude at centro-parietal electrodes (Oz, PO7, O2), and enhanced alpha/beta-band PSD in occipitotemporal regions. Functional connectivity analysis revealed a task-state shift from a frontoparietal to an occipitotemporal network. The multimodal SVM model achieved 86.49% classification accuracy (AUC = 0.86). Conclusion: Task-specific P300 hypoactivity, aberrant oscillatory dynamics, and functional network reorganization collectively distinguish adolescent MDD from HC. These findings provide convergent neurophysiological evidence for impaired cognitive control in MDD and highlight the potential of preliminary candidate EEG biomarkers for early identification, prognostic assessment, and monitoring treatment response in adolescent MDD.
- 26 May 2026
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 17, 1778443
Open AccessTask-state P300 and functional brain network abnormalities in adolescent major depressive disorder: a Stroop paradigm study
Background: Cognitive control deficits are a core feature of adolescent major depressive disorder (MDD), yet the associated task-state neurophysiological mechanisms remain poorly characterized. This study investigated electrophysiological alterations in MDD using a Stroop color-word task. Methods: Twenty-two adolescents with MDD and fifteen age- and sex-matched healthy controls (HC) completed the task during 32-channel EEG recording. We analyzed P300 amplitude and latency, 1-30Hz power spectral density (PSD) in key cortical regions, and task-based functional connectivity using the phase locking value (PLV). A support vector machine (SVM) classifier with leave-one-out cross-validation was employed to assess the diagnostic utility of the multimodal features. Results: Relative to HC, the MDD group exhibited significantly prolonged incongruent trial reaction times, reduced P300 amplitude at centro-parietal electrodes (Oz, PO7, O2), and enhanced alpha/beta-band PSD in occipitotemporal regions. Functional connectivity analysis revealed a task-state shift from a frontoparietal to an occipitotemporal network. The multimodal SVM model achieved 86.49% classification accuracy (AUC = 0.86). Conclusion: Task-specific P300 hypoactivity, aberrant oscillatory dynamics, and functional network reorganization collectively distinguish adolescent MDD from HC. These findings provide convergent neurophysiological evidence for impaired cognitive control in MDD and highlight the potential of preliminary candidate EEG biomarkers for early identification, prognostic assessment, and monitoring treatment response in adolescent MDD.
- Open Access
- 7 May 2026
- Published by Frontiers Media SA in Frontiers in Psychology
- Vol. 17, 1831835
A prospective, single-center, quasi-experimental study protocol for evaluating the efficacy of stepwise Yalom group therapy in reducing depressive symptoms and interpersonal problems in Chinese female patients with depressive disorders
Background: Depressive disorder is affecting significantly more women than men. It is often accompanied by interpersonal difficulties, which severely impair patients’ social functioning. Individual interpersonal therapy can help improve interpersonal problems, but the implementation of individual therapy is more difficult than that of group therapy. This study aims to evaluate the efficacy of Yalom group therapy in reducing depressive symptoms and interpersonal difficulties among Chinese women with depressive disorders. Methods: A total of 90 participants will be allocated to either the intervention group or the control group. Inclusion criteria: ① Diagnosis of depressive disorder or recurrent depressive disorder according to the International Classification of Diseases, 10th Revision (ICD-10), confirmed by two attending physicians or above; ② Female sex; ③ Age ≥18 years and p < 0.05 will be considered statistically significant. Discussion: This study will enhance understanding of the application of Yalom group therapy in female patients with depressive disorders. As the first study in China to implement a full-course intervention for female inpatients with depressive disorders, it will provide insights into the utility of Yalom group therapy for mitigating disease severity and improving interpersonal outcomes in this population. Clinical trial registration: https://www.chictr.org.cn/ , identifier ChiCTR2600116067
- 7 May 2026
- Published by Frontiers Media SA in Frontiers in Psychology
- Vol. 17, 1831835
Open AccessA prospective, single-center, quasi-experimental study protocol for evaluating the efficacy of stepwise Yalom group therapy in reducing depressive symptoms and interpersonal problems in Chinese female patients with depressive disorders
Background: Depressive disorder is affecting significantly more women than men. It is often accompanied by interpersonal difficulties, which severely impair patients’ social functioning. Individual interpersonal therapy can help improve interpersonal problems, but the implementation of individual therapy is more difficult than that of group therapy. This study aims to evaluate the efficacy of Yalom group therapy in reducing depressive symptoms and interpersonal difficulties among Chinese women with depressive disorders. Methods: A total of 90 participants will be allocated to either the intervention group or the control group. Inclusion criteria: ① Diagnosis of depressive disorder or recurrent depressive disorder according to the International Classification of Diseases, 10th Revision (ICD-10), confirmed by two attending physicians or above; ② Female sex; ③ Age ≥18 years and p < 0.05 will be considered statistically significant. Discussion: This study will enhance understanding of the application of Yalom group therapy in female patients with depressive disorders. As the first study in China to implement a full-course intervention for female inpatients with depressive disorders, it will provide insights into the utility of Yalom group therapy for mitigating disease severity and improving interpersonal outcomes in this population. Clinical trial registration: https://www.chictr.org.cn/ , identifier ChiCTR2600116067
- Open Access
- 6 May 2026
- Published by Wiley in Addiction Biology
- Vol. 31 (5) , e70166
Virtual Reality–Based Cue Exposure and Aversion Therapy for Alcohol Dependence: A Randomized Controlled Trial
Alcohol dependence ( AD ) is characterized by a high relapse rate. Virtual reality (VR) technology can provide immersive cue exposure therapy (VR‐CET) and aversion therapy (VR‐AT). This study aimed to evaluate the efficacy of VR‐CET, VR‐AT and their combination on craving, emotional and sleep states, attentional bias and relapse rate in patients with AD . In this single‐centre randomized controlled trial, male inpatients with AD were randomly assigned to one of four groups: control, VR‐CET, VR‐AT or combined VR‐CET + AT (target n = 25 per group; 80 completed, 20 per group). The interventions spanned 15 days with eight sessions (VR‐CET + AT ~20 min/session; others ~10 min). Assessments were conducted before and after treatment using the Visual Analogue Scale (VAS), the Pennsylvania Alcohol Craving Scale (PACS), the Hamilton Depression Scale (HAMD), the Hamilton Anxiety Scale (HAMA) and the Pittsburgh Sleep Quality Index (PSQI). Eye‐tracking and grasping indices in VR environments were used to assess attentional bias (e.g., alcohol‐cue fixation time ratio). Relapse was evaluated by telephone at 4 and 12 weeks post‐treatment. Statistical analyses used Shapiro–Wilk tests and ANOVA/Kruskal–Wallis tests with appropriate post hoc comparisons ( α = 0.05). All groups showed significant pre‐ to post‐treatment improvements in PACS, HAMD, HAMA, PSQI and VAS scores (all p < 0.001). Between‐group comparisons at post‐treatment revealed significant differences in alcohol‐cue fixation time ratio ( p < 0.05), with the VR‐CET + AT group showing a lower fixation time ratio than the control group. VAS scores also differed among groups ( p < 0.05), with the control group showing higher values than the VR‐CET + AT group. Changes in alcohol‐cue fixation time ratio from pre‐ to post‐treatment were significantly greater in the VR‐CET + AT group than in the control group. Relapse rates at 4 and 12 weeks (47/80 reached by telephone follow‐up) did not significantly differ among groups (both p > 0.05). Combining VR‐CET with VR‐AT reduced craving (VAS) and attentional bias (alcohol‐cue fixation time ratio) beyond standard care, whereas all groups improved on clinical scales. Larger and longer trials are warranted to further clarify relapse outcomes. Trial Registration: Chinese Clinical Trial Registry, ChiCTR2500110026. Registered 29 September 2025 (retrospectively registered)
- 6 May 2026
- Published by Wiley in Addiction Biology
- Vol. 31 (5) , e70166
Open AccessVirtual Reality–Based Cue Exposure and Aversion Therapy for Alcohol Dependence: A Randomized Controlled Trial
Alcohol dependence ( AD ) is characterized by a high relapse rate. Virtual reality (VR) technology can provide immersive cue exposure therapy (VR‐CET) and aversion therapy (VR‐AT). This study aimed to evaluate the efficacy of VR‐CET, VR‐AT and their combination on craving, emotional and sleep states, attentional bias and relapse rate in patients with AD . In this single‐centre randomized controlled trial, male inpatients with AD were randomly assigned to one of four groups: control, VR‐CET, VR‐AT or combined VR‐CET + AT (target n = 25 per group; 80 completed, 20 per group). The interventions spanned 15 days with eight sessions (VR‐CET + AT ~20 min/session; others ~10 min). Assessments were conducted before and after treatment using the Visual Analogue Scale (VAS), the Pennsylvania Alcohol Craving Scale (PACS), the Hamilton Depression Scale (HAMD), the Hamilton Anxiety Scale (HAMA) and the Pittsburgh Sleep Quality Index (PSQI). Eye‐tracking and grasping indices in VR environments were used to assess attentional bias (e.g., alcohol‐cue fixation time ratio). Relapse was evaluated by telephone at 4 and 12 weeks post‐treatment. Statistical analyses used Shapiro–Wilk tests and ANOVA/Kruskal–Wallis tests with appropriate post hoc comparisons ( α = 0.05). All groups showed significant pre‐ to post‐treatment improvements in PACS, HAMD, HAMA, PSQI and VAS scores (all p < 0.001). Between‐group comparisons at post‐treatment revealed significant differences in alcohol‐cue fixation time ratio ( p < 0.05), with the VR‐CET + AT group showing a lower fixation time ratio than the control group. VAS scores also differed among groups ( p < 0.05), with the control group showing higher values than the VR‐CET + AT group. Changes in alcohol‐cue fixation time ratio from pre‐ to post‐treatment were significantly greater in the VR‐CET + AT group than in the control group. Relapse rates at 4 and 12 weeks (47/80 reached by telephone follow‐up) did not significantly differ among groups (both p > 0.05). Combining VR‐CET with VR‐AT reduced craving (VAS) and attentional bias (alcohol‐cue fixation time ratio) beyond standard care, whereas all groups improved on clinical scales. Larger and longer trials are warranted to further clarify relapse outcomes. Trial Registration: Chinese Clinical Trial Registry, ChiCTR2500110026. Registered 29 September 2025 (retrospectively registered)
- Open Access
- 13 March 2026
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 17, 1777266
Comprehensive intervention for reducing suicidal ideation and depressive symptoms in adolescents with non-suicidal self-injury: a study of Internet-delivered and offline dialectical behavior therapy
Objective: This study aims to evaluate the efficacy of a comprehensive intervention—Internet-integrated and offline dialectical behavior therapy (DBT)—in reducing suicidal ideation and depressive symptoms and improving cognitive emotion regulation among adolescent non-suicidal self-injury (NSSI). Methods: Adolescent patients with NSSI ( n = 120) who were discharged from the follow-up system of The Second Affiliated Hospital of Xinxiang Medical University were enrolled in this study (from September 2022 to October 2024).The control group received Internet-delivered DBT training, while the experimental group received Internet-delivered and offline-DBT sessions. The intervention lasted for 1 year. All participants completed the following questionnaires: Self-Rating Idea of Suicide Scale (SIOSS), Cognitive Emotion Regulation Questionnaire (CERQ-C), and Montgomery–Asberg Depression Rating Scale (MADRS) to evaluate suicidal ideation, cognitive–emotional regulation, and depressive symptoms. Assessments were conducted at baseline, 6 months, and 12 months. Repeated-measures ANOVA was employed to compare the health status of the two groups at different time points. Results: In the control group ( n = 55) and the experimental group ( n = 53), the main effects of the SIOSS optimistic and concealing factor, total score, CERQ-C dimension scores, and MADRS scores were found to be significant ( P < 0.05). Additionally, the main effects of time on SIOSS factors and total score, CERQ-C dimension scores, and MADRS scores were significant ( P < 0.05). Furthermore, there was an interactive effect between groups and time on the SIOSS sleep and concealing factor scores, CERQ-C self-blame, contemplation, active refocus, refocus plans, and active reappraisal scores ( P < 0.05). Conclusions: Comprehensive intervention effectively mitigates suicidal ideation, alleviates depressive symptoms, enhances cognitive emotion regulation ability, and improves the quality of life in adolescents with NSSI.
- 13 March 2026
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 17, 1777266
Open AccessComprehensive intervention for reducing suicidal ideation and depressive symptoms in adolescents with non-suicidal self-injury: a study of Internet-delivered and offline dialectical behavior therapy
Objective: This study aims to evaluate the efficacy of a comprehensive intervention—Internet-integrated and offline dialectical behavior therapy (DBT)—in reducing suicidal ideation and depressive symptoms and improving cognitive emotion regulation among adolescent non-suicidal self-injury (NSSI). Methods: Adolescent patients with NSSI ( n = 120) who were discharged from the follow-up system of The Second Affiliated Hospital of Xinxiang Medical University were enrolled in this study (from September 2022 to October 2024).The control group received Internet-delivered DBT training, while the experimental group received Internet-delivered and offline-DBT sessions. The intervention lasted for 1 year. All participants completed the following questionnaires: Self-Rating Idea of Suicide Scale (SIOSS), Cognitive Emotion Regulation Questionnaire (CERQ-C), and Montgomery–Asberg Depression Rating Scale (MADRS) to evaluate suicidal ideation, cognitive–emotional regulation, and depressive symptoms. Assessments were conducted at baseline, 6 months, and 12 months. Repeated-measures ANOVA was employed to compare the health status of the two groups at different time points. Results: In the control group ( n = 55) and the experimental group ( n = 53), the main effects of the SIOSS optimistic and concealing factor, total score, CERQ-C dimension scores, and MADRS scores were found to be significant ( P < 0.05). Additionally, the main effects of time on SIOSS factors and total score, CERQ-C dimension scores, and MADRS scores were significant ( P < 0.05). Furthermore, there was an interactive effect between groups and time on the SIOSS sleep and concealing factor scores, CERQ-C self-blame, contemplation, active refocus, refocus plans, and active reappraisal scores ( P < 0.05). Conclusions: Comprehensive intervention effectively mitigates suicidal ideation, alleviates depressive symptoms, enhances cognitive emotion regulation ability, and improves the quality of life in adolescents with NSSI.
- Open Access
- 1 March 2026
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 22, 1-10
Lurasidone in Schizophrenia Management: A Comprehensive 12-Week Post-Marketing Surveillance Study in Chinese Patients
Objective: To evaluate the safety and effectiveness of lurasidone in Chinese patients with schizophrenia in a 12-week post-marketing study. Methods: This 12-week, multicenter, prospective, open-label, single-arm study included schizophrenia patients from 36 sites in Mainland China, who initiated lurasidone between September 2019 and December 2023. Adverse events (AEs) and adverse drug reactions (ADRs) were primary safety endpoints. Other safety assessments included extrapyramidal symptoms (EPS) and weight gain. Effectiveness was evaluated using the Brief Psychiatric Rating Scale (BPRS) at baseline and week 12. Patients were also stratified to assess differences across ages. Results: A total of 3170 patients were included in the Full Analysis Set (FAS) and 3178 in the Safety Set (SS). The mean daily lurasidone dose was 59.9± 20.93 mg. ADRs occurred in 7.9% of patients, with incidences of 8.1%, 8.9%, 5.9%, and 2.3% in the < 18, 18– 45, 45– 65, and > 65-year age groups, respectively. EPS was the most common ADR (3.2%), typically emerging in weeks 3– 4. Metabolic-related AEs occurred in 4.3% and 2.2% of patients with and without metabolic affecting agents. BPRS scores significantly improved at weeks 2/4, 6/8, and 12 compared with baseline (all P < 0.05): total score (− 8.9 ± 9.62, − 14.0 ± 12.16, − 17.5 ± 13.61), anxiety-depression (− 1.5 ± 2.37, − 2.5 ± 2.88, − 3.3 ± 3.31), anergia (− 1.5 ± 2.34, − 2.4 ± 2.83, − 3.1 ± 3.11), thought disturbance (− 2.4 ± 2.98, − 3.8 ± 3.72, − 4.7 ± 4.07), activation (− 1.2 ± 1.97, − 1.7 ± 2.38, − 2.1 ± 2.63), and hostility-suspiciousness (− 2.4 ± 2.81, − 3.6 ± 3.44, − 4.3 ± 3.76). In < 18 years group, BPRS total score also significantly decreased from 46.1± 15.10 at baseline to 26.3± 9.72 at week 12. Conclusion: This real-world study demonstrated a favorable safety profile and significant clinical effectiveness of lurasidone in both adult and adolescent population with schizophrenia in China in real-world clinical settings, supporting its use across diverse patient populations. Trial Registration: Shanghai Clinical Research Center for Mental Health (SCRC-MH) NCT04432688. URL: www.smhc.org.cn/.
- 1 March 2026
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 22, 1-10
Open AccessLurasidone in Schizophrenia Management: A Comprehensive 12-Week Post-Marketing Surveillance Study in Chinese Patients
Objective: To evaluate the safety and effectiveness of lurasidone in Chinese patients with schizophrenia in a 12-week post-marketing study. Methods: This 12-week, multicenter, prospective, open-label, single-arm study included schizophrenia patients from 36 sites in Mainland China, who initiated lurasidone between September 2019 and December 2023. Adverse events (AEs) and adverse drug reactions (ADRs) were primary safety endpoints. Other safety assessments included extrapyramidal symptoms (EPS) and weight gain. Effectiveness was evaluated using the Brief Psychiatric Rating Scale (BPRS) at baseline and week 12. Patients were also stratified to assess differences across ages. Results: A total of 3170 patients were included in the Full Analysis Set (FAS) and 3178 in the Safety Set (SS). The mean daily lurasidone dose was 59.9± 20.93 mg. ADRs occurred in 7.9% of patients, with incidences of 8.1%, 8.9%, 5.9%, and 2.3% in the < 18, 18– 45, 45– 65, and > 65-year age groups, respectively. EPS was the most common ADR (3.2%), typically emerging in weeks 3– 4. Metabolic-related AEs occurred in 4.3% and 2.2% of patients with and without metabolic affecting agents. BPRS scores significantly improved at weeks 2/4, 6/8, and 12 compared with baseline (all P < 0.05): total score (− 8.9 ± 9.62, − 14.0 ± 12.16, − 17.5 ± 13.61), anxiety-depression (− 1.5 ± 2.37, − 2.5 ± 2.88, − 3.3 ± 3.31), anergia (− 1.5 ± 2.34, − 2.4 ± 2.83, − 3.1 ± 3.11), thought disturbance (− 2.4 ± 2.98, − 3.8 ± 3.72, − 4.7 ± 4.07), activation (− 1.2 ± 1.97, − 1.7 ± 2.38, − 2.1 ± 2.63), and hostility-suspiciousness (− 2.4 ± 2.81, − 3.6 ± 3.44, − 4.3 ± 3.76). In < 18 years group, BPRS total score also significantly decreased from 46.1± 15.10 at baseline to 26.3± 9.72 at week 12. Conclusion: This real-world study demonstrated a favorable safety profile and significant clinical effectiveness of lurasidone in both adult and adolescent population with schizophrenia in China in real-world clinical settings, supporting its use across diverse patient populations. Trial Registration: Shanghai Clinical Research Center for Mental Health (SCRC-MH) NCT04432688. URL: www.smhc.org.cn/.
- Open Access
- 24 February 2026
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 17, 1742634
Efficacy and mechanisms underlying MRI-guided HD-tDCS combined with aerobic exercise to ameliorate cognitive impairment associated with schizophrenia
Background: The primary treatment for schizophrenia currently relies on medication. Nevertheless, the efficacy of medication for Cognitive Impairment Associated with Schizophrenia (CIAS) is constrained, and it is also accompanied by side effects. Consequently, the investigation of novel non-pharmacological strategies is essential. High-definition transcranial direct current stimulation (HD-tDCS) and aerobic exercise (AE) have emerged as promising approaches for cognitive enhancement in individuals with schizophrenia. This study aims to evaluate the efficacy of integrating HD-tDCS with AE for CIAS and to elucidate the underlying mechanisms of this synergistic intervention. Methods: A randomized, double-blind, controlled trial will be conducted. The CIAS will be randomly allocated to one of four groups: MRI-guided HD-tDCS + AE, MRI-guided HD-tDCS alone, AE alone, and a control group. Structural magnetic resonance imaging (MRI) data will be obtained to determine the optimal electrode placement. The central electrode will be positioned over the medial prefrontal cortex (mPFC). Both HD-tDCS and AE will be administered five times per week over a four-week period, resulting in a total of 20 sessions. The primary outcome measure will be the change in cognitive function, evaluated using the MATRICS Consensus Cognitive Battery. Secondary outcomes will include changes assessed by the Repeatable Battery for the Assessment of Neuropsychological Status and the Wisconsin Card Sorting Test which are designed to evaluate global and executive functions. The Facial Emotion Perception Test and the Voice Emotion Perception Test will be utilized to assess social cognition. The severity of clinical symptoms will be quantified through the Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. This study will incorporate functional near-infrared spectroscopy, MRI, electroencephalography, P300 event-related potential, eye movement examination and plasma brain-derived neurotrophic factor (BDNF) levels to investigate the underlying mechanisms. Assessments will be evaluated at baseline (T0), after 2 weeks (T1), after 4 weeks (T2), and after 6 months (T3). Discussion: The integration of MRI-guided HD-tDCS targeting the mPFC and AE presents an efficacious and individualized treatment strategy for CIAS. This proof-of-concept study may provide a multi-dimensional view of biological mechanisms underlying HD-tDCS combined with AE in precision psychiatry. Trial registration details: The study is registered with https://www.chictr.org.cn/ protocol registration number ChiCTR2500106980 (date of registration: 1. August. 2025). It was approved by the Research Ethics Committee of the Second Affiliated Hospital of Xinxiang Medical University (Approval Code: XYEFYLL-2025-16, Approval Date: 17 February 2025). Recruitment began in December 2025.
- 24 February 2026
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 17, 1742634
Open AccessEfficacy and mechanisms underlying MRI-guided HD-tDCS combined with aerobic exercise to ameliorate cognitive impairment associated with schizophrenia
Background: The primary treatment for schizophrenia currently relies on medication. Nevertheless, the efficacy of medication for Cognitive Impairment Associated with Schizophrenia (CIAS) is constrained, and it is also accompanied by side effects. Consequently, the investigation of novel non-pharmacological strategies is essential. High-definition transcranial direct current stimulation (HD-tDCS) and aerobic exercise (AE) have emerged as promising approaches for cognitive enhancement in individuals with schizophrenia. This study aims to evaluate the efficacy of integrating HD-tDCS with AE for CIAS and to elucidate the underlying mechanisms of this synergistic intervention. Methods: A randomized, double-blind, controlled trial will be conducted. The CIAS will be randomly allocated to one of four groups: MRI-guided HD-tDCS + AE, MRI-guided HD-tDCS alone, AE alone, and a control group. Structural magnetic resonance imaging (MRI) data will be obtained to determine the optimal electrode placement. The central electrode will be positioned over the medial prefrontal cortex (mPFC). Both HD-tDCS and AE will be administered five times per week over a four-week period, resulting in a total of 20 sessions. The primary outcome measure will be the change in cognitive function, evaluated using the MATRICS Consensus Cognitive Battery. Secondary outcomes will include changes assessed by the Repeatable Battery for the Assessment of Neuropsychological Status and the Wisconsin Card Sorting Test which are designed to evaluate global and executive functions. The Facial Emotion Perception Test and the Voice Emotion Perception Test will be utilized to assess social cognition. The severity of clinical symptoms will be quantified through the Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. This study will incorporate functional near-infrared spectroscopy, MRI, electroencephalography, P300 event-related potential, eye movement examination and plasma brain-derived neurotrophic factor (BDNF) levels to investigate the underlying mechanisms. Assessments will be evaluated at baseline (T0), after 2 weeks (T1), after 4 weeks (T2), and after 6 months (T3). Discussion: The integration of MRI-guided HD-tDCS targeting the mPFC and AE presents an efficacious and individualized treatment strategy for CIAS. This proof-of-concept study may provide a multi-dimensional view of biological mechanisms underlying HD-tDCS combined with AE in precision psychiatry. Trial registration details: The study is registered with https://www.chictr.org.cn/ protocol registration number ChiCTR2500106980 (date of registration: 1. August. 2025). It was approved by the Research Ethics Committee of the Second Affiliated Hospital of Xinxiang Medical University (Approval Code: XYEFYLL-2025-16, Approval Date: 17 February 2025). Recruitment began in December 2025.
- 21 February 2026
- Published by Elsevier in Neuroscience
- Vol. 601, 14-28
Maternal immune activation impairs neurodevelopment in offspring via ASK1/MAPK-mediated apoptotic disruption during early development
- 21 February 2026
- Published by Elsevier in Neuroscience
- Vol. 601, 14-28
Maternal immune activation impairs neurodevelopment in offspring via ASK1/MAPK-mediated apoptotic disruption during early development
- Open Access
- 2 February 2026
- Published by IMR Press in ALPHA PSYCHIATRY
- Vol. 27 (1)
Efficacy and Mechanisms Underlying MRI-guided High-definition Transcranial Direct Current Stimulation Combined With Computerized Cognitive Remediation Therapy for Improving Cognitive Impairments in Schizophrenia: Study Protocol for a Randomized Controlled Trial
Background: Schizophrenia primarily depends on pharmacotherapy, which has demonstrated limited efficacy in enhancing cognitive impairments. High-definition transcranial direct current stimulation (HD-tDCS) and computerized cognitive remediation therapy (CCRT) hold potential for improving cognitive impairments. This study aims to investigate the effects of combining HD-tDCS with CCRT on cognition and to explore the mechanisms of this approach in schizophrenia. Study Design: This is the protocol of a randomized controlled trial. Methods: Schizophrenia patients will be randomly assigned to one of 4 groups: HD-tDCS + CCRT group (Group 1), HD-tDCS group (Group 2), CCRT group (Group 3), and a control group (Group 4). The central electrode will be personalized using magnetic resonance imaging (MRI)-guided localization in the medial prefrontal cortex (mPFC). CCRT includes 6 therapeutic modules and 10 distinct tasks. Both HD-tDCS and CCRT will be administered once daily, 5 days per week, for 4 consecutive weeks, culminating in a total of 20 sessions. Assessments will occur at baseline (T0), after 10 sessions (T1), after 20 sessions (T2), and after 6 months of follow-up (T3). The primary outcome measure is the change in cognition. We will employ multimodal MRI, serum concentrations of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) to explore the underlying mechanisms. Expected Results: An involvement of mPFC and synaptic plasticity in response to HD-tDCS and CCRT is hypothesized. Conclusion: The study will provide empirical evidence for the effectiveness of combined therapy at an individual level, explore its mechanisms, and may ultimately result in personalized medicine. Clinical Trial Registration: ChiCTR2500102731, https://www.chictr.org.cn/hvshowprojectEN.html?id=276964&v=1.0.
- 2 February 2026
- Published by IMR Press in ALPHA PSYCHIATRY
- Vol. 27 (1)
Open AccessEfficacy and Mechanisms Underlying MRI-guided High-definition Transcranial Direct Current Stimulation Combined With Computerized Cognitive Remediation Therapy for Improving Cognitive Impairments in Schizophrenia: Study Protocol for a Randomized Controlled Trial
Background: Schizophrenia primarily depends on pharmacotherapy, which has demonstrated limited efficacy in enhancing cognitive impairments. High-definition transcranial direct current stimulation (HD-tDCS) and computerized cognitive remediation therapy (CCRT) hold potential for improving cognitive impairments. This study aims to investigate the effects of combining HD-tDCS with CCRT on cognition and to explore the mechanisms of this approach in schizophrenia. Study Design: This is the protocol of a randomized controlled trial. Methods: Schizophrenia patients will be randomly assigned to one of 4 groups: HD-tDCS + CCRT group (Group 1), HD-tDCS group (Group 2), CCRT group (Group 3), and a control group (Group 4). The central electrode will be personalized using magnetic resonance imaging (MRI)-guided localization in the medial prefrontal cortex (mPFC). CCRT includes 6 therapeutic modules and 10 distinct tasks. Both HD-tDCS and CCRT will be administered once daily, 5 days per week, for 4 consecutive weeks, culminating in a total of 20 sessions. Assessments will occur at baseline (T0), after 10 sessions (T1), after 20 sessions (T2), and after 6 months of follow-up (T3). The primary outcome measure is the change in cognition. We will employ multimodal MRI, serum concentrations of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) to explore the underlying mechanisms. Expected Results: An involvement of mPFC and synaptic plasticity in response to HD-tDCS and CCRT is hypothesized. Conclusion: The study will provide empirical evidence for the effectiveness of combined therapy at an individual level, explore its mechanisms, and may ultimately result in personalized medicine. Clinical Trial Registration: ChiCTR2500102731, https://www.chictr.org.cn/hvshowprojectEN.html?id=276964&v=1.0.